We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gastric Cancer: Trastuzumab Trial Results Spur Search for Other Targets.
- Authors
Hede, Karyn
- Abstract
The article discusses the first randomized prospective phase III trial testing trastuzumab (Herceptin) in gastric cancer which demonstrated a median survival beyond a year, 13.8 months. The study also showed that it is beneficial to target human epidermal growth factor receptor 2 (HER2) in gastric cancer patients to curtail cancer growth. Roche-Genentech, the maker of Herceptin has decided to seek regulatory approvals worldwide for the use of the drug in the treatment of advanced gastric cancer.
- Subjects
TRASTUZUMAB; ANTINEOPLASTIC agents; STOMACH cancer; CANCER chemotherapy; CANCER treatment; HER2 protein; TUMOR growth; ROCHE-Genentech (Company)
- Publication
JNCI: Journal of the National Cancer Institute, 2009, Vol 101, Issue 19, p1306
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djp341